Dr. Lawrence E. Flaherty, MD

Dr. Flaherty practices at Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care.

Dr. Flaherty's NPI, 1124065610, was assigned on June 1, 2006. Dr. Flaherty graduated from Saint Louis University School of Medicine in 1978. Dr. Flaherty holds Michigan license 4301050152.

Dr. Flaherty's primary practice is Karmanos Cancer Center, at 4100 John R, Detroit, MI 48201 in Wayne County. The practice phone is (800) 576-6266.

Dr. Flaherty's primary practice is Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care. The medical group on file is Wayne Health. Dmand AI also links Dr. Flaherty to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Flaherty practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Flaherty's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Flaherty is licensed in Michigan.

CMS data shows 172 Medicare services from Dr. Flaherty across 2 procedure codes in 2024, all of them office visits, for 98 Medicare patients. Medicare paid $10,772 for them.

CMS counts 98 Medicare patients who saw Dr. Flaherty in 2024. The largest group is 65 to 74, with 53 patients. 72% of them have cancer, and 66% have high blood pressure. 18% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Flaherty's median patient age at 67, with 82% women.

In 2024, Dr. Flaherty wrote 105 Medicare Part D claims for 31 patients. 62% of them were for generic drugs. CMS names the drug for 81 of them, across 5 drugs with 11 or more claims each, at $504,264 in total drug cost. In 2023, CMS named 70 claims across 3 drugs.

Dr. Flaherty accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 20 papers to Dr. Flaherty, published from 2011 to 2024. 2014 was the busiest year, with 5. The most frequent topics are Melanoma, Skin Neoplasms and Antineoplastic Agents. Dr. Flaherty has published most often in Cancer. Dr. Flaherty's most frequent co-authors are Vernon K. Sondak, MD, Antoni Ribas, MD and Omid Hamid, MD.

Dmand AI links Dr. Flaherty to 10 clinical trials, 6 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Breast Neoplasms. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 39 general payments to Dr. Flaherty from 5 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 91% of the total. Merck Sharp & Dohme Corporation paid the most, $24,105.

Dr. Flaherty graduated from Saint Louis University School of Medicine in 1978.